Chugai Pharmaceutical (OTCMKTS:CHGCY) Trading 3.3% Higher - Here's What Happened

Chugai Pharmaceutical Co., Ltd. (OTCMKTS:CHGCY - Get Free Report) shares rose 3.3% on Friday . The company traded as high as $27.46 and last traded at $26.42. Approximately 116,407 shares traded hands during mid-day trading, a decline of 40% from the average daily volume of 192,576 shares. The stock had previously closed at $25.57.

Chugai Pharmaceutical Price Performance

The business's fifty day simple moving average is $26.19 and its two-hundred day simple moving average is $23.82. The company has a market cap of $88.41 billion, a PE ratio of 34.89 and a beta of 0.68.

Chugai Pharmaceutical (OTCMKTS:CHGCY - Get Free Report) last issued its quarterly earnings data on Thursday, April 24th. The company reported $0.19 earnings per share for the quarter. The business had revenue of $1.89 billion during the quarter. Chugai Pharmaceutical had a net margin of 33.07% and a return on equity of 21.53%. As a group, analysts predict that Chugai Pharmaceutical Co., Ltd. will post 0.74 EPS for the current year.

Chugai Pharmaceutical Company Profile

Chugai Pharmaceutical Co, Ltd., together with its subsidiaries, engages in the research, development, manufacture, sale, importation, and exportation of pharmaceuticals in Japan and internationally. The company's products for oncology primarily include Avastin, FoundationOne, Polivy, Rozlytrek, Tecentriq, Perjeta, Alecensa, Herceptin, Kadcyla, Rituxan, and Gazyva; Edirol, an Osteoporosis agent; Mircera, an erythropoiesis agent; Oxarol, an agent for secondary hyperparathyroidism; and other diseases comprise Hemlibra, CellCept, Bonviva, Tamiflu, Evrysdi, Ronapreve, Vabysmo, and Enspryng.